Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL

    Journal of the American College of Cardiology Date published:

  • Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

    Journal of the American Heart Association Date published:

  • Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%

    Circulation Date published:

  • Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

    JACC: Heart Failure Date published:

  • Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

    Diabetes, Obesity and Metabolism Date published:

  • THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE KIDNEY FUNCTION: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL

    Date published:

  • Renoprotection with semaglutide and liraglutide: Direct or indirect effects?

    Date published:

  • EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS

    Date published:

  • REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6

    Date published:

  • Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

    American Journal of Kidney Diseases Date published:

  • Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

    Nephrology Dialysis Transplantation Date published:

  • Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials

    Journal of the American Society of Nephrology Date published:

  • Letters to the Editor: When should treatment be started for hypertension?

    Australian Prescriber Date published:

  • The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

    The Lancet Rheumatology Date published:

  • Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial

    Date published:

  • SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    The Lancet Diabetes & Endocrinology Date published: